Wednesday, 26 August 2026European Markets

PCI BIOTECH HOLD Stock Over 13% Down So Far On Monday

Loading stream...

(VIANEWS) - Shares of PCI BIOTECH HOLD (Oslo Børs Benchmark Index_GI: PCIB.OL) slid by a staggering 13.25% to kr1.80 at 11:44 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is jumping 0.86% to kr1,214.91, following the last session's upward trend. This seems, at the moment, a somewhat positive trend exchanging session today.

PCI BIOTECH HOLD's last close was kr2.08, 65.18% below its 52-week high of kr5.96.

About PCI BIOTECH HOLD

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.54.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -64.36%.

Volatility

PCI BIOTECH HOLD's last week, last month's, and last quarter's current intraday variation average was 0.97%, 0.37%, and 3.77%.

PCI BIOTECH HOLD's highest amplitude of average volatility was 4.64% (last week), 3.17% (last month), and 3.77% (last quarter).

Volume

Today's last reported volume for PCI BIOTECH HOLD is 78976 which is 40.72% below its average volume of 133238.

Moving Average

PCI BIOTECH HOLD's value is way below its 50-day moving average of kr2.08 and way below its 200-day moving average of kr2.38.

More news about PCI BIOTECH HOLD (PCIB.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com